Horizon Technology Finance Provides $35 Million Venture Loan Facility to GT Medical Technologies
Horizon Technology Finance (NASDAQ: HRZN) has provided a $35 million venture loan facility to GT Medical Technologies, Inc. (GT MedTech), with $15 million initially funded. GT MedTech's flagship product, 骋补尘尘补罢颈濒别庐, is a bioresorbable collagen tile embedded with radiation seeds (Cesium-131) for treating brain tumors. This innovative solution delivers targeted radiation directly to the tumor cavity, reducing recurrence and minimizing exposure to healthy tissue.
GT MedTech, backed by investors like MVM Partners and Glide Healthcare Partners, will use the loan for growth and working capital. The FDA-cleared GammaTile aims to transform brain tumor treatment standards while offering a cost-effective reimbursement profile for hospitals.
Horizon Technology Finance (NASDAQ: HRZN) ha fornito una linea di prestito per venture capital di 35 milioni di dollari a GT Medical Technologies, Inc. (GT MedTech), con 15 milioni di dollari inizialmente finanziati. Il prodotto di punta di GT MedTech, 骋补尘尘补罢颈濒别庐, 猫 un tiles di collagene bioassorbibile dotato di semi radioattivi (Cesio-131) per il trattamento dei tumori cerebrali. Questa soluzione innovativa eroga radiazioni mirate direttamente alla cavit脿 tumorale, riducendo la recidiva e minimizzando l'esposizione ai tessuti sani.
GT MedTech, sostenuta da investitori come MVM Partners e Glide Healthcare Partners, utilizzer脿 il prestito per crescita e capitale circolante. GammaTile, approvato dalla FDA, punta a trasformare gli standard di trattamento dei tumori cerebrali offrendo al contempo un profilo di rimborso conveniente per gli ospedali.
Horizon Technology Finance (NASDAQ: HRZN) ha proporcionado una l铆nea de pr茅stamo de capital de riesgo de 35 millones de d贸lares a GT Medical Technologies, Inc. (GT MedTech), con 15 millones de d贸lares inicialmente financiados. El producto principal de GT MedTech, 骋补尘尘补罢颈濒别庐, es un azulejo de col谩geno bioabsorbible incrustado con semillas radiactivas (Cesio-131) para el tratamiento de tumores cerebrales. Esta soluci贸n innovadora entrega radiaci贸n dirigida directamente a la cavidad del tumor, reduciendo la recurrencia y minimizando la exposici贸n a los tejidos sanos.
GT MedTech, respaldada por inversionistas como MVM Partners y Glide Healthcare Partners, utilizar谩 el pr茅stamo para crecimiento y capital circulante. GammaTile, aprobado por la FDA, tiene como objetivo transformar los est谩ndares de tratamiento de tumores cerebrales mientras ofrece un perfil de reembolso rentable para los hospitales.
順鸽澕鞚挫 韰岉伂雴�搿滌 韺岇澊雮胳姢(NASDAQ: HRZN)電� GT 氅旊敂旎� 韰岉伂雴�搿滌鞀�, Inc. (GT MedTech)鞐� 3500毵� 雼煬 攴滊鞚� 氩れ矘 雽�於� 鞁滌劋鞚� 鞝滉车頄堨溂氅�, 鞚� 欷� 1500毵� 雼煬臧� 觳橃潓鞙茧 鞛愱笀 歆�鞗愲悩鞐堧嫟. GT MedTech鞚� 欤茧牓 鞝滍拡鞚� 臧愲韮赌鞚悸�鞚� 氚╈偓靹� 鞌晽(靹胳姌-131)鞚� 雮挫灔霅� 靸濍秳頃挫劚 旖滊澕瓴� 韮�鞚�搿� 雵岇鞏� 旃橂鞐� 靷毄霅滊嫟. 鞚� 順侅嫚鞝侅澑 靻旊（靺橃潃 膦呾枒 瓿惦彊鞐� 歆侅爲 響滌爜 氚╈偓靹犾潉 鞝勲嫭頃橃棳 鞛皽鞚� 欷勳澊瓿� 瓯搓皶頃� 臁办鞐� 雽�頃� 雲胳稖鞚� 斓滌唽頇旐暅雼�.
GT MedTech電� MVM 韺岉姼雱堨姢鞕� 旮�霛检澊霌� 項姢旒�鞏� 韺岉姼雱堨姢鞕� 臧欖潃 韴瀽鞛愲摛鞚� 歆�鞗愳潉 氚涭晞 靹膘灔瓿� 鞖挫榿 鞛愲掣鞚� 鞙勴暣 雽�於滉笀鞚� 靷毄頃� 瓴冹澊雼�. FDA 鞀轨澑鞚� 氚涭潃 臧愲韮�鞚检潃 雵岇鞏� 旃橂 響滌鞚� 順侅嫚頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌ 氤戩洂鞐� 雽�頃� 牍勳毄 須湪鞝侅澑 靸來櫂 頂勲頃�鞚� 鞝滉车頃滊嫟.
Horizon Technology Finance (NASDAQ: HRZN) a accord茅 une facilit茅 de pr锚t de capital-risque de 35 millions de dollars 脿 GT Medical Technologies, Inc. (GT MedTech), avec 15 millions de dollars financ茅s initialement. Le produit phare de GT MedTech, 骋补尘尘补罢颈濒别庐, est un carreau en collag猫ne bioabsorbable int茅gr茅 avec des graines radioactives (C茅sium-131) pour le traitement des tumeurs c茅r茅brales. Cette solution innovante d茅livre des radiations cibl茅es directement dans la cavit茅 tumorale, r茅duisant les r茅cidives et minimisant l'exposition aux tissus sains.
GT MedTech, soutenue par des investisseurs comme MVM Partners et Glide Healthcare Partners, utilisera le pr锚t pour croissance et fonds de roulement. Le GammaTile, approuv茅 par la FDA, vise 脿 transformer les normes de traitement des tumeurs c茅r茅brales tout en offrant un profil de remboursement rentable pour les h么pitaux.
Horizon Technology Finance (NASDAQ: HRZN) hat eine 35-惭颈濒濒颈辞苍别苍-顿辞濒濒补谤-痴别苍迟耻谤别-顿补谤濒别丑别苍蝉蹿补锄颈濒颈迟盲迟 an GT Medical Technologies, Inc. (GT MedTech) bereitgestellt, wobei zun盲chst 15 Millionen Dollar finanziert wurden. Das Flaggschiffprodukt von GT MedTech, 骋补尘尘补罢颈濒别庐, ist ein bioabbaubarer Kollagenteil, das mit radioaktiven Samen (Cesium-131) zur Behandlung von Hirntumoren ausgestattet ist. Diese innovative L枚sung liefert gezielte Strahlung direkt in die Tumorkavit盲t, reduziert R眉ckf盲lle und minimiert die Exposition gegen眉ber gesundem Gewebe.
GT MedTech, unterst眉tzt von Investoren wie MVM Partners und Glide Healthcare Partners, wird das Darlehen f眉r Wachstum und Betriebskapital verwenden. Das von der FDA zugelassene GammaTile zielt darauf ab, die Behandlungsstandards f眉r Hirntumoren zu revolutionieren und gleichzeitig ein kostenwirksames R眉ckerstattungsprofil f眉r Krankenh盲user zu bieten.
- Secured $35 million venture loan facility from Horizon Technology Finance
- FDA-cleared 骋补尘尘补罢颈濒别庐 offers innovative brain tumor treatment
- Potential to transform standard of care in brain tumor treatment
- Cost-effective reimbursement profile for hospitals
- Backed by top-tier investors including MVM Partners and Glide Healthcare Partners
- None.
Insights
The
GT Medical Technologies' GammaTile represents a significant advancement in brain tumor treatment. The product's unique approach of delivering targeted radiation directly to the tumor cavity addresses a critical need in post-surgical care. The FDA clearance of GammaTile is a major regulatory milestone, indicating its safety and efficacy. The technology's ability to minimize radiation exposure to healthy tissue while delivering a high dose to the tumor site could potentially improve patient outcomes and quality of life. From a research perspective, this innovation could spark further studies on targeted radiation therapies and inspire new approaches to treating other types of cancers. The venture loan facility could accelerate clinical research and real-world evidence generation, which are important for wider adoption in the medical community.
The
GT MedTech, through its innovative flagship product, GammaTile庐, offers a proprietary solution to treat brain tumors. GammaTile is a bioresorbable collagen tile embedded with radiation seeds (Cesium-131), an isotope used to deliver a high dose of radiation directly to the tumor cavity, helping to reduce tumor recurrence. Unlike external beam radiation therapy, GammaTile uses surgically targeted radiation therapy, minimizing excess radiation exposure to healthy tissue.
GT MedTech is backed by top-tier investors including MVM Partners, Glide Healthcare Partners, MedTech Venture Partners and BlueStone Venture Partners. The company will use the loan proceeds for general growth and working capital.
鈥淕T MedTech is pioneering brain tumor treatment with its FDA-cleared GammaTile,鈥� said Gerald A. Michaud, President of Horizon. 鈥淭his solution will help transform the standard of care, while offering a cost-effective reimbursement profile to hospitals, creating a clear win for all stakeholders in the healthcare ecosystem.鈥�
鈥淲e are delighted to have Horizon鈥檚 support as we expand the reach of our groundbreaking GammaTile solution,鈥� said Per Langoe, Chief Executive Officer of GT MedTech. 鈥淏y delivering targeted radiation immediately after tumor removal, GammaTile provides focused radiation to the tumor cavity, helping eradicate residual tumor cells. Our partnership with Horizon Technology Finance will allow us to continue our strategic commercial and market expansion initiatives, helping bring GammaTile to more patients in need.鈥�
About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio鈥檚 return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in
About GT Medical Technologies, Inc.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. GammaTile is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in
Forward-Looking Statements
Statements included herein may constitute 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company鈥檚 filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
View source version on businesswire.com:
Investor Relations:
ICR
Garrett Edson
ir@horizontechfinance.com
(860) 284-6450
Media Relations:
ICR
Chris Gillick
HorizonPR@icrinc.com
(646) 677-1819
GT Medical Technologies, Inc. Media Relations:
GT Medical Technologies
Lori Kagan
lkagan@gtmedtech.com
New Dawn Communications
Dawn Fallon
dfallon@newdawncomms.com
Source: Horizon Technology Finance Corporation
FAQ
What is the size of the venture loan facility provided by Horizon Technology Finance (HRZN) to GT Medical Technologies?
What is GT Medical Technologies' flagship product for brain tumor treatment?
How does 骋补尘尘补罢颈濒别庐 differ from traditional radiation therapy for brain tumors?
What will GT Medical Technologies use the loan proceeds for?
